Octreotide acetate(CAS#83150-76-9)

Octreotide acetate(CAS#83150-76-9)

quality
This product is a synthetic octapeptide analogue of somatostatin. It shares with natural somatostatin the 4 peptide sequences (benzene, chromostatin, lys, and sul) required as an enhancer of activity. However, because octreotide includes two D-amino acids and a deformed threonine, it is more tolerant to the degradation of plasma peptidase and has a longer half-life (about 30-fold) than growth inhibition. The pharmacological effect of this product is similar to that of natural somatostatin, which can inhibit serotonin, vasoactive intestinal peptide (VIP), insulin, glucagon, secretin, motilin and pancreatic polypeptide. It is stronger and more selective than natural growth inhibition for inhibiting growth hormone secretion and less effective for insulin release. The effect of octreotide on susceptible target tissues may be modulated by its promoter effect on cell surface somatostatin receptors. Half-life 1. 5h。

use
For the control of symptoms of metastatic carcinoid and adenocarcinoma secreting vasoactive intestinal peptide; Treatment of acromegaly, pancreatic fistula, dysregulation of peptide hormone secretion of tumor hormonal diarrhea, non-neoplastic diarrhea, treatment of dumping syndrome after gastrectomy.
Usage and dosage For metastatic carcinoids, 100 ug per day for the first two weeks, divided into 2~4 doses. Some carcinoid patients have daily 1. 5mg。 For adenocarcinoma (VIP), 200~300ug per day for the first two weeks. All are injected subcutaneously.
Specification: 0 per vial. 05mg／mL、0.Img]mL、0.5mg／mL。
security
The side effects of this product include abdominal pain, bloating, diarrhea, and steatorrhea; gallstone formation; Glucose tolerance may be reduced or worsened initially on treatment and may improve subsequently; There was no endogenous antibody production after long-term use, and there was no obvious rebound or adverse reaction when the drug was discontinued or rapidly tapered. It can be stored for a long time at 2~8°C.